Jasper Therapeutics, Inc.(JSPR)Earnings, Financials & Key Ratios

JSPR•NASDAQ

$0.48

Price updated Jul 7, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryCell and Gene Therapy Developers

AboutJasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.Show more

Revenue$0
EBITDA-$79M-6.1%
Net Income-$76M-6.4%
EPS (Diluted)-3.95+19.2%
ROE-230.31%-126.4%

JSPR Price & Volume

Jasper Therapeutics, Inc. (JSPR) stock price & volume — 10-year historical chart

Loading chart...

Clinical Development Costs Threaten Capital Base Sustainability

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Contracting

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Clinical trial funding exhaustion

Key Thesis Takeaways

Jasper Therapeutics faces a precarious financial outlook as it continues to fund the clinical development of briquilimab without generating meaningful commercial revenue.
The company's reliance on external capital is underscored by a rapid erosion of its equity base, which has fallen to $3.4 million as of 2026Q1.
Investors should monitor the company's ability to reach critical clinical milestones before its remaining $14.1 million cash position is fully exhausted.

Verdict Logic

the company's equity has eroded to a precarious $3.4 million, and the rapid depletion of cash reserves to $14.1 million suggests a high risk of near-term dilutive financing.

JSPR Growth Metrics

Jasper Therapeutics, Inc. (JSPR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM29.26%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM32.51%

Return on Capital

10 Years-94.54%

5 Years-110.05%

3 Years-133.14%

Last Year-184.59%

Peers Comparison

Key metrics vs top competitors for Jasper Therapeutics, Inc. (JSPR)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
JSPRJasper Therapeutics, Inc.Current	$0.48	$7.83M	-0.12	—	—	-230.31%	—
BEAMBeam Therapeutics Inc.	$37.92	$3.9B	-46.81	120.01%	-49.17%	-5.89%	—
EDITEditas Medicine, Inc.	$3.75	$367.15M	-2.08	25.39%	-281.59%	-677.39%	—
CRSPCRISPR Therapeutics AG	$60.77	$5.86B	-9.39	-89.97%	-13856.54%	-30.88%	—
NTLAIntellia Therapeutics, Inc.	$17.43	$1.96B	-4.57	16.92%	-597.04%	-57.27%	—
FATEFate Therapeutics, Inc.	$3.02	$352.01M	-2.63	-51.24%	-2056.79%	-58.89%	—